@article {7086,
	title = {Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis},
	journal = {American Journal of Hematology},
	volume = {91},
	year = {2016},
	note = {Cited By :3Export Date: 18 February 2017References: Dimopoulos, M.A., Terpos, E., Chanan-Khan, A., Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group (2010) J Clin Oncol, 28, pp. 4976-4984;Augustson, B.M., Begum, G., Dunn, J.A., Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party (2005) J Clin Oncol, 23, pp. 9219-9226; 
Tsakiris, D.J., Stel, V.S., Finne, P., Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: An ERA-EDTA Registry study (2010) Nephrol Dial Transplant, 25, pp. 1200-1206; 
Hutchison, C.A., Blade, J., Cockwell, P., Novel approaches for reducing free light chains in patients with myeloma kidney (2012) Nat Rev Nephrol, 8, pp. 234-243; 
Kastritis, E., Terpos, E., Dimopoulos, M.A., Current treatments for renal failure due to multiple myeloma (2013) Expert Opin Pharmacother, 14, pp. 1477-1495; 
Terpos, E., Kleber, M., Engelhardt, M., European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications (2015) Haematologica, 100, pp. 1254-1266; 
Dimopoulos, M.A., Roussou, M., Gkotzamanidou, M., The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma (2013) Leukemia, 27, pp. 423-429; 
Levey, A.S., Bosch, J.P., Lewis, J.B., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (1999) Modification of Diet in Renal Disease Study Group. Ann Intern Med, 130, pp. 461-470; 
Durie, B.G., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; 
Chanan-Khan, A.A., Kaufman, J.L., Mehta, J., Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study (2007) Blood, 109, pp. 2604-2606; 
San-Miguel, J.F., Richardson, P.G., Sonneveld, P., Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study (2008) Leukemia, 22, pp. 842-849; 
Ludwig, H., Drach, J., Graf, H., Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma (2007) Haematologica, 92, pp. 1411-1414; 
Ludwig, H., Adam, Z., Hajek, R., Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study (2010) J Clin Oncol, 28, pp. 4635-4641; 
Dimopoulos, M.A., Roussou, M., Gavriatopoulou, M., Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: Identification of predictive factors (2009) Clin Lymphoma Myeloma, 9, pp. 302-306; 
Roussou, M., Kastritis, E., Migkou, M., Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens (2008) Leuk Lymphoma, 49, pp. 890-895; 
Hutchison, C.A., Bradwell, A.R., Cook, M., Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis (2009) Clin J Am Soc Nephrol, 4, pp. 745-754; 
Hutchison, C.A., Heyne, N., Airia, P., Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis (2012) Nephrol Dial Transplant; 
Dimopoulos, M.A., Kastritis, E., Rosinol, L., Pathogenesis and treatment of renal failure in multiple myeloma (2008) Leukemia, 22, pp. 1485-1493; 
Badros, A.Z., Vij, R., Martin, T., Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety (2013) Leukemia, 27, pp. 1707-1714; 
Shah, J.J., Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib (2013) Oncology (Williston Park), 3, pp. 19-23; 
Smith, D.C., Kalebic, T., Infante, J.R., Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies (2015) Invest New Drugs, 33, pp. 652-663; 
Kumar, S.K., Bensinger, W.I., Zimmerman, T.M., Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma (2014) Blood, 124, pp. 1047-1055; 
Kumar, S.K., Berdeja, J.G., Niesvizky, R., Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study (2014) Lancet Oncol, 15, pp. 1503-1512; 
Richardson, P.G., Baz, R., Wang, M., Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients (2014) Blood, 124, pp. 1038-1046; 
Ludwig, H., Rauch, E., Kuehr, T., Lenalidomide and dexamethasone for acute light chain-induced renal failure: A phase II study (2015) Haematologica, 100, pp. 385-391; 
Dimopoulos, M.A., Christoulas, D., Roussou, M., Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: Dosing of lenalidomide according to renal function and effect on renal impairment (2010) Eur J Haematol, 85, pp. 1-5; 
Dimopoulos, M., Alegre, A., Stadtmauer, E.A., The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function (2010) Cancer, 116, pp. 3807-3814; 
Dimopoulos, M.A., Cheung, M.C., Roussel, M., Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma (2015) Haematologica, , Dec 11. pii: haematol.2015.133629. [Epub ahead of print]; 
Oehrlein, K., Langer, C., Sturm, I., Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: Results of 4 German centers (2012) Clin Lymphoma Myeloma Leuk, 12, pp. 191-196; 
de la Rubia, J., Roig, M., Ibanez, A., Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: A Spanish multicenter retrospective study (2010) Eur J Haematol, 85, pp. 363-365; 
Dimopoulos, M.A., Sonneveld, P., Siegel, D., Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors (2015) Ann Oncol, 26, pp. 2247-2256; 
Dimopoulos, M.A., Leleu, X., Palumbo, A., Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) Leukemia, 28, pp. 1573-1585
},
	month = {2016},
	pages = {499 - 502},
	abstract = {Renal failure (RF) is a common and severe complication of symptomatic myeloma, associated with significant morbidity and mortality. Such patients are commonly excluded from clinical trials. Bortezomib/dexamethasone (VD)-based regimens are the backbone of the treatment of newly diagnosed MM patients who present with severe RF even those requiring dialysis. We analyzed the outcomes of 83 consecutive bortezomib-treated patients with severe RF (eGFR\&lt;30 ml/min/1.73 m2), of which 31 (37\%) required dialysis. By IMWG renal response criteria, 54 (65\%) patients achieved at least MRrenal, including CRrenal in 35\% and PRrenal in 12\%. Triplet combinations (i.e., VD plus a third agent) versus VD alone were associated with higher rates of renal responses (72 vs. 50\%; P=0.06). Fifteen of the 31 (48\%) patients became dialysis independent within a median of 217 days (range 11-724). Triplets were associated with a higher probability of dialysis discontinuation (57 vs. 35\%). Serum free light chain (sFLC) level >=11,550 mg/L was associated with lower rates of major renal response, longer time to major renal response, lower probability, and longer time to dialysis discontinuation. Rapid myeloma response (>=PR within the first month) was also associated with higher rates of renal response. Patients who became dialysis-independent had longer survival than those remaining on dialysis. In conclusion, VD-based triplets are associated with a significant probability of renal response and dialysis discontinuation, improving the survival of patients who became dialysis independent. Rapid disease response is important for renal recovery and sFLCs are predictive of the probability and of the time required for renal response. {\textcopyright} 2016 Wiley Periodicals, Inc.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963520672\&doi=10.1002\%2fajh.24335\&partnerID=40\&md5=62f81f9bce8e3d5b2f2b86be01fa6555},
	author = {Dimopoulos, M.A. and Roussou, M. and Gavriatopoulou, M. and Psimenou, E. and Eleutherakis-Papaiakovou, E. and Migkou, M. and Matsouka, C. and Mparmparousi, D. and Gika, D. and Kafantari, E. and Ziogas, D. and Fotiou, D. and Panagiotidis, I. and Terpos, E. and Kastritis, E.}
}
